MCL-1 but not BCL-XL is critical for the development and sustained expansion of thymic lymphoma in p53-deficient mice

Blood

Volumn 124, Issue 26, 2014, Pages 3939-3946

  Grabow, Stephanie ^a,b   Delbridge, Alex R D ^a,b   Valente, Liz J ^a,b   Strasser, Andreas ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CRE RECOMBINASE; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN P53; TAMOXIFEN; BCL2L1 PROTEIN, MOUSE; MCL1 PROTEIN, MOUSE; MYELOID LEUKEMIA FACTOR 1; PROTEIN BCL X;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INCIDENCE; CANCER SURVIVAL; CANCER TRANSPLANTATION; CONTROLLED STUDY; GENE TARGETING; LIVER METASTASIS; LIVER WEIGHT; LOXP SITE; LYMPHOID CELL; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SPLEEN WEIGHT; T CELL LYMPHOMA; THYMUS LYMPHOMA; WESTERN BLOTTING; ANIMAL; APOPTOSIS; C57BL MOUSE; CELL SURVIVAL; CELL TRANSPLANTATION; CYTOLOGY; GENE DELETION; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; METABOLISM; MUTATION; PHYSIOLOGY; STEM CELL; THYMOMA; TUMOR SUPPRESSOR GENE;

ALLELES; ANIMALS; APOPTOSIS; BCL-X PROTEIN; CELL SURVIVAL; CELL TRANSPLANTATION; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, P53; GENOTYPE; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; MUTATION; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; STEM CELLS; THYMUS NEOPLASMS;

EID: 84919497247     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-09-601567     Document Type: Article

References (44)

1. Vousden KH, Lane DP. p53 in health and disease. Nat Rev Mol Cell Biol. 2007;8(4):275-283.
2. Malkin D, Li FP, Strong LC, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 1990;250(4985):1233-1238.
3. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature. 1990;348(6303):747-749.
4. Riley T, Sontag E, Chen P, Levine A. Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 2008;9(5):402-412.
5. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
6. Jacks T, Remington L, Williams BO, et al. Tumor spectrum analysis in p53-mutant mice. Curr Biol. 1994;4(1):1-7.
7. Lang GA, Iwakuma T, Suh YA, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell. 2004; 119(6):861-872.
8. Olive KP, Tuveson DA, Ruhe ZC, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119(6):847-860.
9. Strasser A, O'Connor L, Dixit VM. Apoptosis signaling. Annu Rev Biochem. 2000;69:217-245.
10. Czabotar PE, Lessene G, Strasser A, Adams JM. Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol. 2014;15(1):49-63.
11. Huang DCS, Strasser A. BH3-Only proteinsessential initiators of apoptotic cell death. Cell. 2000;103(6):839-842.
12. Chipuk JE, Green DR. How do BCL-2 proteins induce mitochondrial outer membrane permeabilization? Trends Cell Biol. 2008;18(4):157-164.
13. Youle RJ, Strasser A. The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 2008;9(1):47-59.
14. Strasser A, Cory S, Adams JM. Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 2011;30(18):3667-3683.
15. Llambi F, Moldoveanu T, Tait SW, et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell. 2011;44(4):517-531.
16. Kelly PN, Grabow S, Delbridge ARD, Strasser A, Adams JM. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood. 2011;118(24):6380-6386.
17. Kelly PN, Grabow S, Delbridge AR, Adams JM, Strasser A. Prophylactic treatment with the BH3 mimetic ABT-737 impedes Myc-driven lymphomagenesis in mice. Cell Death Differ. 2013;20(1):57-63.
18. Kelly PN, Puthalakath H, Adams JM, Strasser A. Endogenous bcl-2 is not required for the development of Emu-myc-induced B-cell lymphoma. Blood. 2007;109(11):4907-4913.
19. Xiang Z, Luo H, Payton JE, et al. Mcl1 haploinsufficiency protects mice from Mycinduced acute myeloid leukemia. J Clin Invest. 2010;120(6):2109-2118.
20. Glaser SP, Lee EF, Trounson E, et al. Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes Dev. 2012;26(2):120-125.
21. Vikstrom I, Carotta S, Lüthje K, et al. Mcl-1 is essential for germinal center formation and B cell memory. Science. 2010;330(6007):1095-1099.
22. Wagner KU, Claudio E, Rucker EB III, et al. Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development. 2000; 127(22):4949-4958.
23. Orban PC, Chui D, Marth JD. Tissue- and sitespecific DNA recombination in transgenic mice. Proc Natl Acad Sci USA. 1992;89(15):6861-6865.
24. Seibler J, Zevnik B, Küter-Luks B, et al. Rapid generation of inducible mouse mutants. Nucleic Acids Res. 2003;31(4):e12.
25. Anastassiadis K, Glaser S, Kranz A, Berhardt K, Stewart AF. A practical summary of site-specific recombination, conditional mutagenesis, and tamoxifen induction of CreERT2. Methods Enzymol. 2010;477:109-123.
26. Okamoto T, Coultas L, Metcalf D, et al. Enhanced stability of Mcl1, a prosurvival Bcl2 relative, blunts stress-induced apoptosis, causes male sterility, and promotes tumorigenesis. Proc Natl Acad Sci USA. 2014;111(1):261-266.
27. Rinkenberger JL, Horning S, Klocke B, Roth K, Korsmeyer SJ. Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev. 2000;14(1):23-27.
28. Michalak EM, Vandenberg CJ, Delbridge AR, et al. Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. Genes Dev. 2010;24(15):1608-1613.
29. Labi V, Erlacher M, Krumschnabel G, et al. Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. Genes Dev. 2010;24(15):1602-1607.
30. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC, Korsmeyer SJ. Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature. 2003;426(6967):671-676.
31. Kelly GL, Grabow S, Glaser SP, et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014;28(1):58-70.
32. Villunger A, Michalak EM, Coultas L, et al. p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science. 2003;302(5647):1036-1038.
33. Erlacher M, Michalak EM, Kelly PN, et al. BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood. 2005;106(13):4131-4138.
34. Happo L, Cragg MS, Phipson B, et al. Maximal killing of lymphoma cells by DNA damage-inducing therapy requires not only the p53 targets Puma and Noxa, but also Bim. Blood. 2010;116(24):5256-5267.
35. Valente LJ, Gray DH, Michalak EM, et al. p53 efficiently suppresses tumor development in the complete absence of its cell-cycle inhibitory and proapoptotic effectors p21, Puma, and Noxa. Cell Reports. 2013;3(5):1339-1345.
36. Grabow S, Waring P, Happo L, et al. Pharmacological blockade of Bcl-2, Bcl-x(L) and Bcl-w by the BH3 mimetic ABT-737 has only minor impact on tumour development in p53-deficient mice. Cell Death Differ. 2012;19(4):623-632.
37. Boise LH, Minn AJ, Noel PJ, et al. CD28 costimulation can promote T cell survival by enhancing the expression of Bcl-XL. Immunity. 1995;3(1):87-98.
38. Kaplan HS, Brown MB. Protection against radiation-induced lymphoma development by shielding and partial-body irradiation of mice. Cancer Res. 1952;12(6):441-444.
39. Opferman JT, Iwasaki H, Ong CC, et al. Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science. 2005;307(5712):1101-1104.
40. Koss B, Morrison J, Perciavalle RM, et al. Requirement for antiapoptotic MCL-1 in the survival of BCR-ABL B-lineage acute lymphoblastic leukemia. Blood. 2013;122(9):1587-1598.
41. Bouillet P, Metcalf D, Huang DC, et al. Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science. 1999;286(5445):1735-1738.
42. Egle A, Harris AW, Bouillet P, Cory S. Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA. 2004;101(16):6164-6169.
43. Ventura A, Kirsch DG, McLaughlin ME, et al. Restoration of p53 function leads to tumour regression in vivo. Nature. 2007;445(7128):661-665.
44. Souers AJ, Leverson JD, Boghaert ER, et al. ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med. 2013;19(2):202-208.